The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

Польза статинов у людей без установленного сердечно-сосудистого заболевания, но с факторами риска сердечно-сосудистых заболеваний: метаанализ рандомизированных контролируемых исследований
Paul M. Ridker, Jaap Willem Deckers, Jasper Jan Brugts, Rudi G. J. Westendorp, Anton J.M. de Craen, Antonio M. Gotto, J. Shepherd, Robert H. Knopp, Sanne Elisabeth Hoeks, Tuncay Yetgin, H. Nakamura, Ronald van Domburg, J Shepherd
2009-06-30

cardiovascular risk factorsmajor cardiovascular eventsmeta-analysis of randomized controlled trialsprimary preventionstatins
OBJECTIVES: To investigate whether statins reduce all cause mortality and major coronary and cerebrovascular events in people without established cardiovascular disease but with cardiovascular risk factors, and whether these effects are similar in men and women, in young and older (>65 years) people, and in people with diabetes mellitus. DESIGN: Meta-analysis of randomised trials. DATA SOURCES: Cochrane controlled trials register, Embase, and Medline. Data abstraction Two independent investigators identified studies on the clinical effects of statins compared with a placebo or control group and with follow-up of at least one year, at least 80% or more participants without established cardiovascular disease, and outcome data on mortality and major cardiovascular disease events. Heterogeneity was assessed using the Q and I(2) statistics. Publication bias was assessed by visual examination of funnel plots and the Egger regression test. RESULTS: 10 trials enrolled a total of 70 388 people, of whom 23 681 (34%) were women and 16 078 (23%) had diabetes mellitus. Mean follow-up was 4.1 years. Treatment with statins significantly reduced the risk of all cause mortality (odds ratio 0.88, 95% confidence interval 0.81 to 0.96), major coronary events (0.70, 0.61 to 0.81), and major cerebrovascular events (0.81, 0.71 to 0.93). No evidence of an increased risk of cancer was observed. There was no significant heterogeneity of the treatment effect in clinical subgroups. CONCLUSION: In patients without established cardiovascular disease but with cardiovascular risk factors, statin use was associated with significantly improved survival and large reductions in the risk of major cardiovascular events.
1
A meta-analysis of 10 randomized trials involving 70,388 participants assessed statins for primary prevention in people with cardiovascular risk factors.
2
No evidence of increased cancer risk was observed with statin treatment.
3
Statin therapy substantially reduced major coronary events (OR 0.70, 95% CI 0.61–0.81) and major cerebrovascular events (OR 0.81, 95% CI 0.71–0.93).
4
Statins significantly reduced all-cause mortality, with an odds ratio of 0.88 (95% CI 0.81–0.96) over a mean 4.1-year follow-up.
5
Treatment effects showed no significant heterogeneity across clinical subgroups, including sex, age, and diabetes status.

People without established cardiovascular disease but with cardiovascular risk factors

The effects of statin treatment on all-cause mortality and major coronary and cerebrovascular events, including consistency across sex, age, and diabetes subgroups

Publication Details
Publication Date
2009-06-30
Journal
Publisher
ISSN
Cited by
795
Access Type
Author Information
Authors
Paul M. Ridker
Jaap Willem Deckers
Jasper Jan Brugts
Rudi G. J. Westendorp
Anton J.M. de Craen
Antonio M. Gotto
J. Shepherd
Robert H. Knopp
Sanne Elisabeth Hoeks
Tuncay Yetgin
H. Nakamura
Ronald van Domburg
J Shepherd
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%